Alzheimer's Association Workgroup Updates Guidance on Amyloid-Related Imaging Abnormalities (ARIA) for Anti-Amyloid Therapies

For patients with Alzheimer's disease (AD), anti-amyloid immunotherapies offer a promising approach to slow disease progression by clearing amyloid plaques. However, these therapies are associated with amyloid-related imaging abnormalities (ARIA), a critical safety concern involving vasogenic edema (ARIA-E) and microhemorrhages/superficial siderosis (ARIA-H). Initial recommendations for detecting and monitoring ARIA were introduced in 2011. With the recent regulatory approval of new monoclonal antibodies, there is an urgent need for updated guidance to ensure patient safety and optimize treatment protocols.

The Alzheimer's Association ARIA workgroup conducted a comprehensive review of new clinical trial data on anti-amyloid immunotherapies for Alzheimer's disease. This update synthesizes evidence from recent trials, including those involving monoclonal antibodies like lecanemab and donanemab, which have demonstrated significant amyloid plaque clearance. The workgroup's task was to refine and update the existing 2011 recommendations for the detection, monitoring, and management of ARIA, providing current best practices for clinicians and researchers based on the evolving landscape of AD treatments.

The workgroup's update highlights a significant shift in anti-amyloid therapy development. Earlier attempts with β-site APP-cleaving enzyme 1 (BACE1) and secretase inhibitors failed in clinical trials due to mechanism-based toxicity and cognitive impairment. In contrast, newer monoclonal antibodies, specifically lecanemab and donanemab, have shown high amyloid plaque clearance and reduced cognitive decline in Alzheimer's disease patients. Despite their therapeutic success, ARIA remains a prevalent side effect. The updated recommendations integrate new data on ARIA incidence, risk factors (e.g., APOE4 genotype), and refined strategies for MRI monitoring and clinical management. This ensures that while patients benefit from amyloid reduction, the risks associated with ARIA are effectively mitigated.

The update confirms that while new monoclonal antibodies effectively clear amyloid plaques and reduce cognitive decline, ARIA remains a critical safety consideration requiring updated monitoring protocols.